Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs Intensive Salvage Therapy in First Relapse AML
NCT00822094Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Feb 2009
- Primary completion
- Dec 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Proportion of Subjects Surviving at 1 Year. Started Feb 2009; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00822094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00822094.